What is it about?
Hypothyroidism is a recognized late adverse event following radiotherapy for head and neck cancer (HNC). In the JCOG1008 trial, we treated patients with high-risk HNC with postoperative chemoradiotherapy. We aimed to elucidate factors associated with hypothyroidism by analyzing the JCOG1008 data.
Featured Image
Photo by National Cancer Institute on Unsplash
Perspectives
Read the Original
This page is a summary of: Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008, Oral Oncology, October 2024, Elsevier,
DOI: 10.1016/j.oraloncology.2024.106976.
You can read the full text:
Contributors
The following have contributed to this page